Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(announced a settlement agreement with Celgene Corporation (NASDAQ: CELG ) regarding its ANDA related to generic Revlimid pending before Health Canada) Down In The Dumps (Biotech stocks hitting 52-week lows on April 2) Evoke Pharma Inc (NASDAQ: EVOK )(FDA issued a complete response letter for Gimoti, which is being evaluated for treating symptoms in adult women with acute and recurrent diabetic gastroparesis. Stock In Focus Advaxis To Offer Common Stock Advaxis, Inc. (NASDAQ: ADXS ), which rallied sharply Monday in reaction to clinical trial updates, announced its intention to offer its common stock in an underwritten public offering. The company said it intends to use the net proceeds to fund its R&D initiatives and for general corporate purposes. The stock slid 15.59 percent to $4.98 in after-hours trading.